GI6301-CHORDOMA
Regimen
- Experimental
- GI-6301 (heat-inactivated yeast expressing brachyury) SC every 2 weeks x3 then monthly, combined with standard radiotherapy
- Control
- Placebo yeast + standard radiotherapy
Population
Locally advanced unresectable chordoma scheduled for standard definitive radiotherapy; brachyury is the near-universal transcription-factor driver in chordoma
Key finding
Numerical response-rate advantage with brachyury vaccine plus radiotherapy but underpowered; toxicity mild. Demonstrated feasibility and immunogenicity of targeting the chordoma master transcription factor.
Source: PMID 33594772